UNSPSC 51111704: Mitomycin

This classification denotes an alkylating agent, antibiotics, antineoplastic, cross-linking reagent, and nucleic acid synthesis inhibitor with the molecular formula C15H18N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50SG953SK6, chemically known as 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2,3:3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester) but generally known as mitomycin, which bears US NIH Compound Identifier 5746.

UNSPSC 51111704 Mitomycin, a Commodity code, covers the procurement of this antitumor antibiotic pharmaceutical by state and local health agencies. Recent state and local activity under this code shows minimal formal solicitation volume; the single identified recent opportunity stems from a health agency pursuing broader pharmacy program reform rather than direct acquisition of mitomycin itself. The Texas Health and Human Services Commission issued Request for Information (RFI) No. HHS0017013 in late March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which would establish direct contracting relationships between state pharmacy benefit programs and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. While the RFI scope encompasses pharmaceutical products broadly, it does not specify mitomycin as a target drug, and the solicitation functions as preliminary market intelligence gathering rather than a formal competitive procurement with binding timelines or award values.

The code shows little recent activity specific to mitomycin procurement. Geographic coverage is limited to Texas based on the single identified opportunity. Issuing bodies pursuing pharmacy initiatives remain state health agencies rather than counties, cities, or school districts. The RFI mechanism suggests that state pharmaceutical procurement strategy is evolving toward direct manufacturer relationships and value-based pricing models, but formal competitive solicitations for specific oncology pharmaceuticals such as mitomycin remain absent from the recent-opportunities record. Firms tracking this code should monitor whether the Texas HHS Commission and other state health agencies issue formal RFPs following this exploratory phase, which would clarify actual mitomycin procurement volumes and contracting terms.